




CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 9, 2005
Date


David L. Parker

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Isaiah J. Fidler
Corazon D. Bucana

Serial No.: 10/010,763

Filed: November 2, 2001

For: METHODS FOR DETECTING THE
EFFICACY OF ANTICANCER
TREATMENTS

Group Art Unit: 1642

Examiner: Ungar, Susan NMN

Atty. Dkt. No.: UTSC:684US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

03/16/2005 EHAILE1 00000020 501212 10010763


01 FC:1806
02 ~~5.00~~ ~~5.00~~ 180.00 0P

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSC:684US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 9, 2005



Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Pollack et al. "Therapy of human carcinomas in athymic mice by inhibition of egf receptor-mediated signal transduction with cp-358774: dynamics of receptor inhibition and anti-tumor effects," <i>Proc Annu Meet Am Assoc Cancer Res</i> , Abstract 4249, 1997.
	C35	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with cp-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>JPET</i> , 291739-748, 1999.
	C36	Prewett et al., "Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 Inhibits the growth of human renal cell carcinoma xenografts in nude mice," <i>Clinical Cancer Research</i> , 4:2957-2966, 1998.
	C37	Prewett et al., "The biologic effects of C225, a chimeric monoclonal antibody to the egfr, on human prostate carcinoma," <i>J of Immunotherapy</i> , 19:419-427, 1997.
	C38	Scardino and Wheeler, "Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy," <i>NCI Monogr</i> , 7:95-103, 1988.

25511056.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.